Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Series A for Pevion Biotech results in CHF35mm

15 Aug 2007

Executive Summary

Pevion Biotech (vaccines for infectious diseases and cancer) raised CHF35mm ($29.3mm) through its Series A financing led by first-time backer BZ Bank Aktiengesellschaft. Other new investors BB Biotech Ventures and CC Private Equity Partners were joined by returning shareholder Bachem Holding AG. The company will use the proceeds to move its Phase I hepatitis C and breast cancer vaccines into Phase II trials, and to advance its preclinical RSV and Candida vaccines into human studies.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By